Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
Illumina's Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?
01:02pm, Thursday, 24'th Oct 2024
In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X.
ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold?
10:05am, Friday, 18'th Oct 2024
Reaching a new one-year high, Illumina remains in investors' sight owing to its strong strategic execution and positive growth outlook.
Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers
12:10pm, Wednesday, 09'th Oct 2024
Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries
Illumina launches compact, low-cost gene sequencing devices
12:05pm, Wednesday, 09'th Oct 2024
Medical equipment maker Illumina on Wednesday announced its new series of smaller, low-cost benchtop gene sequencers, a move that will make sequencing accessible to more research and testing labs.
Here's Why Illumina (ILMN) is a Strong Momentum Stock
10:55am, Tuesday, 08'th Oct 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024
04:05pm, Monday, 07'th Oct 2024
SAN DIEGO , Oct. 7, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2024 following the close of market on Monday, November 4, 2024.�
Revisiting Illumina
12:36am, Monday, 07'th Oct 2024
Illumina's stock has rebounded 25% since October 2023, despite underwhelming revenue growth and challenges with the NovaSeq X platform and macro headwinds. The company faces issues with the adoption o
Charles Dadswell to step down as General Counsel, Illumina initiates search for successor
05:46pm, Thursday, 03'rd Oct 2024
SAN DIEGO , Oct. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that after 11 years of service, Charles "Chuck" Dadswe
Illumina Inc (ILMN) Trading 5.9% Higher on Oct 2
12:08pm, Wednesday, 02'nd Oct 2024
Shares of Illumina Inc (ILMN, Financial) surged 5.90% in mid-day trading on Oct 2. The stock reached an intraday high of $136.82, before settling at $136.59, up from its previous close of $128.98.
GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success
12:41pm, Tuesday, 24'th Sep 2024
GRAIL Inc., spun off from Illumina Inc. in June 2024, faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Despite a strong balance sheet, GRAIL's
Bull of the Day: Illumina (ILMN)
08:01am, Tuesday, 10'th Sep 2024
Big jump after earnings led by a pullback, could be an opportunity here.
MIAMI , Sept. 9, 2024 /PRNewswire/ -- The FDA has granted approval on Illumina's TruSight Oncology Comprehensive Assay, marking a transformative milestone in cancer diagnostics.
European Court of Justice rules in favor of Illumina in jurisdictional appeal
03:59am, Tuesday, 03'rd Sep 2024
SAN DIEGO , Sept. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment toda
EU top court backs Illumina fight against EU probe into Grail deal
03:50am, Tuesday, 03'rd Sep 2024
Europe's top court on Tuesday backed U.S. gene sequencing company Illumina's fight against EU antitrust regulators' investigation into its $7.1 billion bid for cancer diagnostic test maker Grail.
Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology
04:16pm, Thursday, 29'th Aug 2024
Data Support Clinical Performance of Galleri to Detect More Aggressive Prostate Cancers MENLO PARK, Calif. , Aug. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose miss
